Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

NCT04282044 is registered in ClinicalTrials.gov with BioEclipse Therapeutics as lead sponsor.

NCT NCT04282044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04282044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Lead sponsor
BioEclipse Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
January 8, 2021
Completion date
October 31, 2026
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, epithelial ovarian cancer, gastric cancer, hepatocellular carcinoma, malignant melanoma, non-small cell lung cancer, osteosarcoma, solid tumor, adult, triple negative breast cancer